SAN JOSE, Calif., July 16, 2019 /PRNewswire/ -- BioPharmX
Corporation (NYSE American: BPMX), a specialty pharmaceutical
company focused on developing innovative medical dermatology
products, today announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical
industry veteran, as its Chief Operating Officer. Mr. Bosacki
previously served as Senior Vice President and General Counsel
under BioPharmX CEO, Dr. David S.
Tierney, at Oceana Therapeutics. Previously, Mr. Bosacki
served as President and CEO of Lautus Pharmaceuticals, a privately
held pharmaceutical company focused on the dermatology and
aesthetics markets. In his newly appointed role at BioPharmX, Mr.
Bosacki will oversee all operational aspects of the business
including clinical, regulatory, pharmaceutical development and
legal activities.
"I am delighted to once again have the opportunity to work with
Steve. He is a proven executive with a track record of
successfully navigating specialty pharmaceutical companies through
the development and commercialization of their product portfolios,"
said Dr. Tierney, BioPharmX CEO. "He has deep knowledge in the
dermatology space and understands the complexities of the
regulatory process which will prove invaluable as we continue to
advance our topical dermatology programs toward FDA approval."
Mr. Bosacki commented, "I'm excited about the potential of
BioPharmX's proprietary HyantX delivery system and its underlying
product candidates and I am thrilled to be working again with
David."
In addition to Mr. Bosacki's appointment, BioPharmX today
announces that Dr. Kin F. Chan, Executive Vice President of
Research and Technology, has resigned from his position, effective
July 26, 2019, to pursue other
opportunities. Dr. Chan will continue to serve as an advisor to
BioPharmX. Dr. Tierney commented, "On behalf of the board of
directors, I want to thank Dr. Chan for his dedication, leadership
and many contributions to BioPharmX and its topical minocycline
programs over the years. We wish him the best in his future
endeavors."
About Steven M. Bosacki, JD,
MBA
Prior to his appointment as COO at BioPharmX, Mr.
Bosacki served as President and CEO of Lautus Pharmaceuticals, a
privately held pharmaceutical company focused on the dermatology
and aesthetics markets. The Lautus product line was acquired by
Mission Pharmacal in 2016. Following the acquisition, Mr. Bosacki
joined the Mission Pharmacal team to lead its newly formed
aesthetic dermatology division, Espada Dermatology, Inc.
He served as Senior Vice President and General Counsel for
Oceana Therapeutics, Inc., a specialty therapeutic company he
co-founded along with Dr. Tierney. Mr. Bosacki was instrumental in
establishing a global commercial network that ultimately led to
Oceana's acquisition by Salix Pharmaceuticals in 2011. Prior to
Oceana Therapeutics, Mr. Bosacki served as Senior Vice President
and General Counsel for Esprit Pharma, Inc., which was acquired by
Allergan, Inc. in 2007. Earlier in his career, Mr. Bosacki served
in a variety of management positions at Cardinal Health. Mr.
Bosacki received his US and Canadian law degrees from University of Detroit School of Law and
University of Windsor, respectively,
and his MBA and bachelor's degrees from the University of Windsor in Canada.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE American: BPMX) is a specialty pharmaceutical company focused
on developing prescription products utilizing its proprietary
HyantX Topical Delivery System for dermatology indications. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies. These statements involve risks and uncertainties, which
could cause actual results to differ materially from our
predictions, and include, but are not limited to statements about
the company's ability to complete clinical studies and advance its
product candidates through regulatory approval, to commercialize
its drug delivery program and to obtain patent protection and
defend its intellectual property and to raise capital. Additional
risks are set forth in our filings with the Securities and Exchange
Commission, including those described in the company's Quarterly
Report on Form 10-Q for the quarter ended April 30, 2019. The forward-looking statements
included in this press release are made only as of the date hereof,
and the company undertakes no obligation to publicly update such
statements.
BioPharmX and HyantX are registered trademarks of BioPharmX,
Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopharmx-announces-steven-m-bosacki-joins-the-company-as-chief-operating-officer-300885974.html
SOURCE BioPharmX Corporation